ICON Public Limited Company (ICLR) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 65
- Profitability 50
- Business Quality 60
- Balance Sheet 40
- Cash Flow 35
Why this rating?
Health 52/100 — Acceptable
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
ICON Public Limited Company (ICLR) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates ICON Public Limited Company 52/100 (Acceptable) due to solid business quality, steady revenue growth, and elevated leverage.
Investment profile
- Quality Moderate
- Growth Moderate
- Balance Sheet Stretched
- Valuation Attractive
Financial highlights
Valuation
- P/E 192.61
- Forward P/E 15.55
- PEG 0.56
- EV/Revenue 2.01
Profitability
- Revenue Growth 1.2%
- Gross Margin 23.9%
- Operating Margin 9.4%
- Net Margin 0.3%
- ROE 0.3%
Financial strength
- Cash $928.39M
- Debt $3.53B
- Net Cash $-2.60B
- Free Cash Flow $861.99M
- Current Ratio 0.95
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Veracyte, Inc. Diagnostics & Research VCYT$50.28 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Illumina, Inc. Diagnostics & Research ILMN$279.47 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$70.53 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$50.17 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$232.00 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$242.56 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Sotera Health Company Diagnostics & Research SHC$18.49 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$161.86 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks ICON Public Limited Company (ICLR).